Pharmaccess Leaders Forum, 26-28 November 2012, Germany

Main Category: Conferences
Article Date: 08 Aug 2012 - 7:00 PST


Payer & HTA Forum

Day 1/2 - 26th - 27th (am) November, 2012

This meeting will provide an ideal opportunity for "payers", HTAs and other decision makers from both public and private organisations, to benchmark with peers internationally. Attendees will be able to understand and develop best practice approaches to such vital and common challenges, with the ultimate goal of encouraging innovation and improving patient access to novel and powerful medications.

Market Access in Emerging Markets

Day 2/3 - 27th (pm) - 28th November, 2012

This event will bring together experts responsible for emerging markets globally and locally to discuss how the current changing environments, policies and practices will impact on market access in these markets and as a result affecting the success of global strategies. This meeting will showcase experts on pricing, reimbursement, HTA, regulatory affairs, government relations and market & patient access in leading emerging countries.

Initial Experiences with German AMNOG Pricing & Reimbursement Reform

Day 2/3 - 27th (pm) - 28th November, 2012

The German Healthcare system is the EU's largest and best financed, which until recently has used free-market pricing and as such represents a crucial first step in a pharma company's EU launch strategy. The large number of sick funds combined with the free pricing policy has resulted in an extremely competitive environment for pharmaceutical and medical device market leaders to operate in until now. This event will be an excellent opportunity to gain knowledge from real AMNOG experiences and meet the experts who faced and overcame the first challenges that the reform has been presenting.

Achieving Market Access for High-Value Specialty & Biologic Medications

Day 2/3 - 27th (pm) - 28th November, 2012

This event will uniquely look at how to generate quality evidence and demonstrate value to global payers health technology assessors and other key stakeholders for higher-cost drugs prescribed by specialists in various therapeutic areas. Such drugs may include niche biologics, expensive small molecules, orphan drugs, personalized medicines or biosimilars. This event will look at the overcoming the challenge to generate strong evidence to demonstrate value, the latest innovative market access techniques, satisfying HTA requirements to build the right dossier.

To request the full agenda please follow the link: http://www.pharmaccessleadersforum.com/request-agenda

Pharmaccess Leaders Forum
Conference dates: 26-28 November 2012
Venue: Eurostars Hotel, Berlin, Germany

Erika Vavrovicova
Pharmaccess Leaders Forum
Tel: +421 232 660 382
Fax: +421 2 3301 0331
Email: erika@pharmaccessleadersforum.com
Visit: http://www.pharmaccessleadersforum.com/

• Additional
• References
• Citations